WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a virtual panel discussion at the William Blair Biotech Focus Conference 2021 titled “Novel Targets for Autoimmune Diseases,” on Thursday, July 15, 2021 at 11:00 a.m. ET. Management will be available July 15th throughout the day for virtual one-on-one meetings.
A live webcast of the panel discussion may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Contact
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to…
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction…
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science ProDentim…
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2…
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted…
NeuroQuiet Reviews NeuroQuiet VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
